Literature DB >> 10738100

Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein.

K Raviprakash1, T J Kochel, D Ewing, M Simmons, I Phillips, C G Hayes, K R Porter.   

Abstract

Recombinant plasmid DNA constructs expressing truncated or full-length dengue-1 envelope (E) with or without the pre-membrane (prM) were tested for immunogenicity in mice, as candidate dengue DNA vaccines. Two plasmids, one expressing the N-terminal 80% E and the other expressing prM and full length E were immunogenic in intradermally inoculated mice. The vaccinated mice produced dengue-1 specific antibodies that were both neutralizing and long lasting. Data suggested that the plasmid expressing prM and full length E produced virus like particles in transfected cells, and is probably a better immunogen compared to that expressing 80% E.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738100     DOI: 10.1016/s0264-410x(99)00570-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Use of recombinant envelope proteins for serological diagnosis of Dengue virus infection in an immunochromatographic assay.

Authors:  A J Cuzzubbo; T P Endy; A Nisalak; S Kalayanarooj; D W Vaughn; S A Ogata; D E Clements; P L Devine
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

2.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

3.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

4.  Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.

Authors:  Kanakatte Raviprakash; Peifang Sun; Yossef Raviv; Thomas Luke; Nicholas Martin; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

Review 5.  Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

Authors:  Anuja Mathew; Elizabeth Townsley; Francis A Ennis
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

6.  Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties.

Authors:  Wenquan Liu; Hanning Jiang; Junmei Zhou; Xiaomeng Yang; Yunxia Tang; Danyun Fang; Lifang Jiang
Journal:  Virus Genes       Date:  2009-11-03       Impact factor: 2.332

7.  A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.

Authors:  Kanakatte Raviprakash; Thomas Luke; John Doukas; Janine Danko; Kevin Porter; Timothy Burgess; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

8.  A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.

Authors:  Lan Chen; Dan Ewing; Hemavathy Subramanian; Karla Block; Jonathan Rayner; Kimberly D Alterson; Martha Sedegah; Curtis Hayes; Kevin Porter; Kanakatte Raviprakash
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

10.  Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.

Authors:  Mariel E Pérez-Vélez; Teresita García-Nieves; Candimar Colón-Sánchez; Idalí Martínez
Journal:  P R Health Sci J       Date:  2009-09       Impact factor: 0.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.